Denali Therapeutics (DNLI) EBITDA (2017 - 2026)
Denali Therapeutics (DNLI) reported EBITDA of -$129.8 million for Q1 2026, up 2.36% year-over-year from -$126.8 million in Q1 2025, and down 0.65% on a QoQ basis from -$129.0 million in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of EBITDA data on file, last reported at -$129.8 million in Q1 2026.
- Quarterly EBITDA rose 2.36% year-over-year to -$129.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$510.7 million (down 13.34% YoY) and the FY2025 annual result came in at -$513.9 million, down 21.95% from the prior year.
- EBITDA slipped to -$129.8 million in Q1 2026 per DNLI's latest filing, from -$129.0 million in the prior quarter.
- Across five years, EBITDA topped out at $184.5 million in Q2 2023 and bottomed at -$133.0 million in Q1 2025.
- The 5-year median for EBITDA is -$103.7 million (2024), against an average of -$90.2 million.
- The widest annual swing landed in 2023, when EBITDA jumped 398.4%; it then tumbled 154.42% in 2024.
- Tracing DNLI's EBITDA over 5 years: stood at -$93.7 million in 2022, then retreated by 26.11% to -$118.2 million in 2023, then retreated by 0.07% to -$118.3 million in 2024, then slipped by 9.05% to -$129.0 million in 2025, then decreased by 0.65% to -$129.8 million in 2026.
- Per Business Quant, the three latest DNLI EBITDA figures stand at -$129.8 million (Q1 2026), -$129.0 million (Q4 2025), and -$126.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -129.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.81 Mn |
| Dec 31, 2025 | -128.97 Mn |
| Sep 30, 2025 | -126.74 Mn |
| Jun 30, 2025 | -125.22 Mn |
| Mar 31, 2025 | -132.95 Mn |
| Dec 31, 2024 | -118.26 Mn |
| Sep 30, 2024 | -99.00 Mn |
| Jun 30, 2024 | -100.39 Mn |
| Mar 31, 2024 | -103.74 Mn |
| Dec 31, 2023 | -118.18 Mn |
| Sep 30, 2023 | -98.56 Mn |
| Jun 30, 2023 | 184.46 Mn |
| Mar 31, 2023 | -105.41 Mn |
| Dec 31, 2022 | -93.71 Mn |
| Sep 30, 2022 | -102.88 Mn |
| Jun 30, 2022 | -61.82 Mn |
| Mar 31, 2022 | -71.97 Mn |
| Dec 31, 2021 | -77.24 Mn |
| Sep 30, 2021 | -84.74 Mn |
| Jun 30, 2021 | -60.83 Mn |
| Mar 31, 2021 | -70.03 Mn |
| Dec 31, 2020 | 244.63 Mn |
| Sep 30, 2020 | -58.77 Mn |
| Jun 30, 2020 | -59.04 Mn |
| Mar 31, 2020 | -56.28 Mn |
| Dec 31, 2019 | -57.76 Mn |
| Sep 30, 2019 | -46.58 Mn |
| Jun 30, 2019 | -57.79 Mn |
| Mar 31, 2019 | -38.01 Mn |
| Dec 31, 2018 | 78.30 Mn |
| Sep 30, 2018 | -35.29 Mn |
| Jun 30, 2018 | -54.93 Mn |
| Mar 31, 2018 | -24.60 Mn |
| Dec 31, 2017 | -23.02 Mn |
| Sep 30, 2017 | -21.70 Mn |
| Jun 30, 2017 | -22.12 Mn |
| Mar 31, 2017 | -21.34 Mn |